Stay updated on CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial

Sign up to get notified when there's something new on the CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the dosage of CVL-231 (Emraclidine) in a Phase 2 clinical trial for participants with schizophrenia experiencing an acute exacerbation of psychosis.
    Difference
    0.1%
    Check dated 2024-06-06T14:40:07.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    15 days ago
    Change Detected
    Summary
    The value (Estimated) on the webpage has recently changed to . This change likely indicates an update or revision in the estimated completion date of a Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of CVL-231 (Emraclidine) in participants with schizophrenia experiencing an acute exacerbation of psychosis.
    Difference
    0.1%
    Check dated 2024-05-25T04:59:07.000Z thumbnail image
  7. Check
    16 days ago
    Change Detected
    Summary
    The value '03 13 Recruiting Recruiting Recruiting Recruiting 03 12 03 13 03' has changed to '05 23 Active, not recruiting Active, not recruiting Mangonia Park, Florida, United States, 33407-2413 Recruiting Mangonia Park, Florida Withdrawn Houston, Texas, United States, 77043-2735 Recruiting Houston, Texas Irving, Texas, United States, 75062-2323 Recruiting Irving, Texas Withdrawn 05 22 (Estimated) 05 23 05.' This change indicates a shift in the recruitment status of certain locations related to medical and healthcare-related publications and documentation.
    Difference
    3%
    Check dated 2024-05-24T04:06:08.000Z thumbnail image
  8. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying the inclusion and exclusion criteria for participants, such as a primary diagnosis of schizophrenia and specific health conditions. Previously, this section had no information provided.
    Difference
    33%
    Check dated 2024-05-22T21:35:14.000Z thumbnail image
  9. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:36:24.000Z thumbnail image

Stay in the know with updates to CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial page.